Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$1.42 - $3.15 $26,769 - $59,383
-18,852 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$2.65 - $5.08 $6,036 - $11,572
-2,278 Reduced 10.78%
18,852 $55,000
Q4 2021

Feb 11, 2022

SELL
$4.73 - $7.9 $1.01 Million - $1.69 Million
-213,506 Reduced 90.99%
21,130 $101,000
Q3 2021

Nov 04, 2021

BUY
$5.16 - $7.98 $1,491 - $2,306
289 Added 0.12%
234,636 $1.78 Million
Q2 2021

Aug 11, 2021

BUY
$6.45 - $9.09 $127,406 - $179,554
19,753 Added 9.2%
234,347 $1.75 Million
Q1 2021

May 13, 2021

SELL
$7.25 - $13.82 $685,676 - $1.31 Million
-94,576 Reduced 30.59%
214,594 $1.67 Million
Q4 2020

Feb 16, 2021

BUY
$6.87 - $10.48 $2.11 Million - $3.22 Million
307,459 Added 17969.55%
309,170 $2.86 Million
Q3 2020

Nov 12, 2020

BUY
$5.06 - $7.23 $8,657 - $12,370
1,711 New
1,711 $12,000
Q1 2020

May 14, 2020

SELL
$1.44 - $3.95 $6,491 - $17,806
-4,508 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$1.17 - $2.33 $5,985 - $11,920
-5,116 Reduced 53.16%
4,508 $8,000
Q3 2019

Nov 14, 2019

BUY
$1.4 - $2.84 $6,270 - $12,720
4,479 Added 87.06%
9,624 $13,000
Q2 2019

Aug 14, 2019

SELL
$2.75 - $4.89 $20,187 - $35,897
-7,341 Reduced 58.79%
5,145 $13,000
Q1 2019

May 15, 2019

BUY
$4.11 - $5.88 $1,348 - $1,928
328 Added 2.7%
12,486 $57,000
Q4 2018

Feb 14, 2019

SELL
$3.65 - $10.69 $392,444 - $1.15 Million
-107,519 Reduced 89.84%
12,158 $50,000
Q3 2018

Dec 21, 2021

BUY
$8.92 - $17.83 $17,019 - $34,019
1,908 Added 1.62%
119,677 $1.31 Million
Q3 2018

Nov 14, 2018

BUY
$8.92 - $17.83 $925,218 - $1.85 Million
103,724 Added 738.51%
117,769 $1.29 Million
Q2 2018

Apr 21, 2020

BUY
$12.83 - $17.41 $30,278 - $41,087
2,360 Added 20.2%
14,045 $229,000
Q2 2018

Aug 14, 2018

BUY
$12.83 - $17.41 $149,918 - $203,435
11,685 New
11,685 $189,000

Others Institutions Holding SURF

About Surface Oncology, Inc.


  • Ticker SURF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,034,000
  • Description
  • Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...
More about SURF
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.